Inhalation delivery of nucleic acid gene therapies in preclinical drug development


Inhaled gene therapies hold great promise in treating a number of diseases including cystic fibrosis and certain cancers of the lung, but the development of these types of therapies is immensely challenging. Lovelace Biomedical has been and remains at the forefront in translational research for inhaled gene therapies. In this review article, Lovelace Biomedical aerosol scientists describe several of these challenges based on our experience as a preclinical contract research organization with a long history in inhalation delivery and over 15 years of work supporting gene therapy programs. If you need a partner to support your inhaled genetic medicine reach out to scientists at Lovelace Biomedical. 

Read the full review article here.